The complex four-hour surgery was performed by a multidisciplinary team of doctors
The $700 million project is part of Roche’s $50 billion investment in US manufacturing, infrastructure and R&D
The company is bringing precision therapies for gynaecological cancers
The accelerated approval is supported by results from part 1 of the ESSENCE trial
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
